IR-Med Inc., a development stage medical device company, focuses on the development of infra-red light spectroscopy combined with artificial intelligence technology platform to address diagnostic or medical needs. It is developing PressureSafe, a handheld optical monitoring device to support early detection of pressure injuries to the skin and underlying tissue primarily caused by prolonged pressure associated with bed confinement; and Nobiotics, an otoscope to support physicians with an immediate indication as to whether mid-ear infection (Otitis Media), a common malady in children. The company is headquartered in Rosh Pina, Israel.
Company profile
Ticker
IRME
Exchange
Website
CEO
Mr. Ran Ziskind
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Meat-Tech 3D Ltd., MeaTech 3D Ltd.
SEC CIK
Corporate docs
IRS number
844516398
IRME stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
17 Sep 24
8-K
Other Events
10 Sep 24
8-K
IR-MED Appoints Ran Ziskind, Tech Entrepreneur, Growth Manager, and Inventor as Chief Executive Officer
28 Aug 24
10-Q
2024 Q2
Quarterly report
13 Aug 24
S-8
Registration of securities for employees
24 Jul 24
8-K
Departure of Directors or Certain Officers
11 Jul 24
S-1
IPO registration
24 Jun 24
8-K
Entry into a Material Definitive Agreement
10 Jun 24
10-Q
2024 Q1
Quarterly report
13 May 24
Latest ownership filings
No filings
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 753.00 k | 753.00 k | 753.00 k | 753.00 k | 753.00 k | 753.00 k |
Cash burn (monthly) | (no burn) | 131.92 k | 119.33 k | 289.58 k | 124.00 k | 191.25 k |
Cash used (since last report) | n/a | 382.87 k | 346.35 k | 840.47 k | 359.89 k | 555.07 k |
Cash remaining | n/a | 370.13 k | 406.65 k | -87.47 k | 393.11 k | 197.93 k |
Runway (months of cash) | n/a | 2.8 | 3.4 | -0.3 | 3.2 | 1.0 |
Press releases
Methodist Healthcare Adopts IR-MED's PressureSafe™ Device for Usability Study: Decision Support Device Aims to Reduce Substantial Healthcare Burden of Pressure Injuries
10 Sep 24
IR-MED Appoints Ran Ziskind, Tech Entrepreneur, Growth Manager, and Inventor as Chief Executive Officer
28 Aug 24
IR-MED Wins Prestigious Netty Award for Best Up-and-Coming Health Tech Company
21 Aug 24
IR-MED Receives $500,000 Grant from the Israel Innovation Authority to Develop its Platform Technology for the Early Detection of Diabetic Foot Ulcers
15 Jul 24